Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AH volume 8888... That's a good one... Then a trade cancel.
Yes it has wook!! Welcome to the jungle! We got fun and games.
Common baby... HOD close please!
Gull, is this the beginning of our slow climb? :)
I would say yes... Bavi maintanence..
This is old, but I wonder what's so confidential?
Maybe we'll find out September 9 2016??
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
September 30, 2013
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Peregrine Pharmaceuticals, Inc.
File No. 001-32839 - CF#30142
_____________________
Peregrine Pharmaceuticals, Inc. submitted an application under Rule 24b-2requesting an extension of a previous grant
of confidential treatment for information it
excluded from the Exhibits to aForm 10-Q filed on September 9, 2010. Based on representations by Peregrine Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:
Exhibit 10.26 through September 9, 2016
Exhibit 10.27 through September 9, 2016
For the Commission, by the Division of
Corporation Finance, pursuant to
delegated authority:
Elizabeth M. Murphy
Secretar
Thanks Dave! Always appreciated for all you do... Among many others on this board.
http://money.cnn.com/2013/12/16/investing/penny-stock-trader-millionaire/ ... Lemmy, I wish you all the luck in the world... Wish I could do it.
Yup, first Tuesday of every month.... If I see a drop below the low $1.30, I'll see If I got some extra cash in the bank and buy more... Even if it's only 100 bucks worth... From what I owned last year till now... I'm happy with my monthly investments... Hope it pays off one day.
I can see that happening... They are only focused on Bavi Ph3 and Bavi's other trials right now.... I think they will pull it off the shelf sooner or later... But only after bavi is approved and running... Or someone buys Cotara or we partner it.
Because we have a buyer or partner?
This is why SK and family doesn't like the retail shareholders... They see all the negative post about the BOD over and over again... Tearing them apart over and over again... I would hate most shareholders too!!.... Knowing the retail shareholders are probably going to become rich one day on this company... The company "THEY" brought to succeed... While everyone was bitching all the way thru..
Keep up the great work SK, I knew there would be plenty of bumps along the way.... We're getting closer and closer by the day.
I would think that PPHM should start their move later this year when the first trickle of news leaks out about the success of the trial. When the last Stock option grants (these will be much larger than the previous grants) are granted it will be set to start a sustained climb to a much higher PPS.
Words I will hold deep in my mind..
Well buy high then... Just giving you a heads up that it could be a great deal right now.
Buy low lemmy!.. We're in a Ph3 trial and we're only $1.40.. What a bargain.
Also BioB... As I have CLL myself (21 years) It's such a slow growing cancer unlike NSCLC... I was on Rituximab and Flurderbine and they told me it could knock my CLL down for years... I was treated for the first time two years ago... I'm not sure what they seen from 2012 to 2015 unless they took in patients who's CLL was treated and came back aggressive.
Thanks gull... Printed and hanging on the wall next to my desk... Something to read once in awhile while waiting!!
Good luck!
Has anyone on this board ever been invested in another company going thru a Ph3 trial?... I'm wondering when and if the pps started making it's move, at what point thru the trial... Or is pphm so different than other companies that we won't make a move untill approval?
Look at all his other post... eom
We'll try this again with a different introduction... Sooner or later Bavi will be known by millions... Curing the sick in a big way.
So with that said :) Shouldn't we all agree, we be on the down low till everything is ready for exposier.. Bavi & Betabodies will be used on millions... Sooner or later you'll be able to mention the word Bavituximab and everyone will know what your talking about... Especially the ones infected with many different diseases.
Advanced melanoma
In March 2014, an open-label, randomized, two agent, single center trial started combining ipilimumab with phosphatidylserine-targeting immunotherapy bavituximab for the treatment of advanced melanoma, sponsored by University of Texas Southwestern Medical Center. The number of treated patients in arm A (ipilimumab plus bavituximab) will be 16, and in the arm B (ipilimumab only) will be 8. The trial is expected to complete in March 2016.[37][38] Previously, preclinical studies showed that PS targeting antibodies (such as bavituximab) enhance the anti-tumor activity of anti-CTLA-4 and anti-PD-1 antibodies. Tumor growth inhibition correlates with infiltration of immune cells in tumors and induction of adaptive immunity. The combination of these mechanisms promotes strong, localized, anti-tumor responses without the side-effects of systemic immune activation.[39]
Development
MLV & Co Analysts Give Peregrine Pharmaceuticals a $3.50 Price Target (PPHM)
March 13th, 2015 - 0 comments - Filed Under - by Preston Daniels
Share on StockTwits
Peregrine Pharmaceuticals logoInvestment analysts at MLV & Co
set a $3.50 price target on shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) stock in a note issued to investors on Friday. The firm currently has a a “buy” rating on the stock. MLV & Co
‘s target price would indicate a potential upside of 150.00% from the company’s current price.
Separately, analysts at Zacks downgraded shares of Peregrine Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $1.50 price target on the stock in a research note on Monday, February 23rd.
Peregrine Pharmaceuticals (NASDAQ:PPHM) traded down 3.45% during mid-day trading on Friday, hitting $1.40. The stock had a trading volume of 2,230,224 shares. Peregrine Pharmaceuticals has a 1-year low of $1.19 and a 1-year high of $2.43. The stock has a 50-day moving average of $1. and a 200-day moving average of $1.. The company’s market cap is $254.91 million.
Peregrine Pharmaceuticals (NASDAQ:PPHM) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.08) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.08). The company had revenue of $5.68 million for the quarter, compared to the consensus estimate of $4.20 million. During the same quarter last year, the company posted ($0.06) earnings per share. Peregrine Pharmaceuticals’s revenue was up 46.0% compared to the same quarter last year. Analysts expect that Peregrine Pharmaceuticals will post $-0.30 EPS for the current fiscal year.
Peregrine Pharmaceuticals, Inc is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (NASDAQ:PPHM) targeting agent, PGN65, and its brain cancer therapy Cotara.
2016 deal with it.. eom
Oncolym: strike 1.... Cotara: strike 2... Bavituximab: Home Run?
Pretend there is no Cotara... It's on the shelf period!!
Really close... Your gonna have to admit it sooner than later.
Oh we're getting so close now, arnt we realist??.... Right to the bank.
The only true insiders Peregrine has is Garnick and the FDA.... FDA is paying very close attention to Sunrise.
Like I've said... It's a no brainer... There is a reason we're trading in the $1.40's... And you know as well as I do.... Something is very fishy about it... In a good way I believe... We're different, we don't want to be on the map right yet... If you have something huge, you don't flaunt it till all your ducks, eggs and what ever else you have are perfectly lined up in a row... Single file with no accidents in between. Imho.
Dave, I'm special.. I'm a maintenance guy, have CLL and been in this company since 1996... I'm boarding no matter what!! :)
I totally agree Gull... I think at this point it's a no brainer... The FDA already knows it's a go... We just have to go thru the system... Thank you Rob Garnick!... I know you know. :)
Get that to rocket built Loof!!
I say they know bavi is gonna get approved... Their just going thru the phases... I bet an early stop in early 2016.
Exactly to the point! eom
Let's hope so!!... Buy more in the $1.20 $1.30 range.
I have a feeling tomorrow is gonna be a great CC.... Who let the dogs out type of CC.... If I'm wrong, oh well, won't be the first time... Probably around the 10th time.
That's a really, really great post!! True and to the point. Time for a drink as well.
We go up... Not down.
I would definitely put in an early buy order in if that happens!!